Wednesday, November 11, 2026

NVIDIA Rubin Ultra and B200 GPU Platforms Drive Enterprise AI Infrastructure Buildout as Aehr Systems Books $60-80M in AI Chip Testing Equipment

Next-generation GPU platforms from NVIDIA are accelerating enterprise AI deployments while specialized testing infrastructure scales to support production volumes. Aehr Test Systems forecasts $60-80M in AI-focused bookings for H2 FY2026, with lead production customer shipments starting Q1 FY2027. Corvex confidential computing solutions and flexible deployment models from V Gallant and VCI Global are enabling secure, scalable LLM infrastructure.

NVIDIA Rubin Ultra and B200 GPU Platforms Drive Enterprise AI Infrastructure Buildout as Aehr Systems Books $60-80M in AI Chip Testing Equipment
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Aehr Test Systems projects $60-80M in bookings for AI wafer-level and packaged-part burn-in equipment during the second half of fiscal 2026, signaling accelerating production volumes for next-generation AI chips. The company received a "very large forecast" from its lead Sonoma production customer, with shipments expected to begin in Q1 FY2027 starting May 30, 2026.

The testing equipment surge comes as NVIDIA's Rubin Ultra and B200-class GPU platforms move toward production deployment. These next-generation chips require advanced 3D-IC packaging and 4nm PCIe 6 interconnects to deliver the computational performance needed for large language model training and inference at enterprise scale.

Aehr's Silicon Valley test lab has received multiple orders for high-power Sonoma configurations capable of handling up to 2,000 watts per device. The company claims production capacity exceeding 20 systems per month for both wafer-level and packaged-part testing. Partnership expansion with ISE Labs and ASE targets wafer-level and packaged-part testing services for top-tier semiconductor customers in HPC and AI applications.

Enterprise AI infrastructure is scaling through secure deployment solutions and flexible delivery models. Corvex confidential computing platforms address data security requirements for sensitive LLM workloads. V Gallant's Compute-X and VCI Global's Intelli-X offerings provide flexible infrastructure delivery models for organizations scaling AI capabilities without massive upfront capital commitments.

Credo Technology Group, supplying high-speed interconnect solutions for AI data centers, expects GAAP gross margins between 63.8% and 65.8% for Q3 FY2026. The margin profile reflects strong demand for connectivity solutions linking GPU clusters in distributed AI training environments.

Edge AI infrastructure is also advancing. Ensurge Micropower's solid-state microbattery technology targets AI-enabled edge devices requiring compact, high-performance power solutions. The technology addresses power density constraints in distributed AI inference applications where traditional battery form factors create design limitations.

Aehr reported Q2 FY2026 revenue of $9.9M, down 27% year-over-year, with non-GAAP net loss of $1.3M. The company raised $10M through its ATM program in Q2, bringing cash position to $31M. Effective backlog reached $18.3M including $6.5M in post-quarter bookings during the first six weeks of Q3.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score11 source documents11 with a live linkVerifiability: High
  1. [1]Earnings callNasdaq· January 16, 2026
    Aehr Test (AEHR) Q2 2026 Earnings Call Transcript
  2. [2]News articleYahoo Finance· December 1, 2025
    Credo Technology Group Holding Ltd Reports Second Quarter of Fiscal Year 2026 Financial Results
  3. [3]News articleYahoo Finance· February 10, 2026
    Einride to Appoint Former NVIDIA Executive Gary Hicok to Board of Directors
  4. [4]Press releaseGlobeNewswire· December 5, 2025
    Ensurge Micropower ASA – Commencement of subscription period in the Subsequent Offering
  5. [5]Press releaseGlobeNewswire· November 6, 2025
    Ensurge Micropower ASA – Contemplated private placement
  6. [6]News articleYahoo Finance· December 5, 2025
    Stock market today: S&P 500, Nasdaq, Dow rise as Fed-favored PCE inflation data cools
  7. [7]News articleYahoo Finance· March 3, 2026
    Corvex Among the First Companies to Achieve Verified Production Deployment of Confidential Computing for AI on NVIDIA HGX™ B200 Systems
  8. [8]News articleYahoo Finance· February 4, 2026
    Silicon Motion Technology Q4 Earnings Call Highlights
  9. [9]News articleYahoo Finance· February 24, 2026
    The Zacks Analyst Blog Highlights Amphenol, Western Digital, Vertiv, Lumentum and EMCOR
  10. [10]News articleYahoo Finance· March 4, 2026
    VCI Global’s V Gallant Launches Malaysia’s First NVIDIA-Powered AI GPU Computing Center; Debuts Intelli-X Enterprise LLM Platform
  11. [11]Press releaseGlobeNewswire· December 11, 2025
    Wafer Dicing Services Market Set to Exceed US$ 932.9 Million by 2035 | Astute Analytica
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com